AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18829988 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin requirements
Number of subjects: 45
Study 18829988 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycated hemoglobin
Number of subjects: 45
Study 18829988 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein B
Number of subjects: 45
Study 18829988 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 45
Study 18829988 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of diseased vessels
Number of subjects: 45
Study 18829988 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior revascularization
Number of subjects: 45
Study 17457267 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital radiography by image intensifier
Number of subjects: 105
Study 17457267 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiography
Number of subjects: 105
Study 17457267 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital radiography
Number of subjects: 105
Study 15111683 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole (0.5 to 6.0 mg/day)
Number of subjects: 22
Study 15111683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 12196868 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly courses of betamethasone until 33 weeks' gestation or delivery
Number of subjects: 12
Study 12196868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9658849 — intervention group
Group type: EXPERIMENTAL
Intervention: Positioning devices used during surgery
Number of subjects: 24
Study 9658849 — intervention group
Group type: COMPARATOR
Intervention: No positioning devices used during surgery
Number of subjects: 24
Study 7658273 — intervention group
Group type: EXPERIMENTAL
Intervention: Match‐to‐sample odorant discrimination task (MODT) for children aged 5 years and older.
Number of subjects: 92
Study 7658273 — intervention group
Group type: COMPARATOR
Intervention: Identification task (comparison with MODT).
Number of subjects: 92
Study 2692970 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewable cimetidine (200 mg)
Number of subjects: 80
Study 2692970 — intervention group
Group type: COMPARATOR
Intervention: Chewable antacid
Number of subjects: 80
Study 347921 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized racemic epinephrine
Number of subjects: 20
Study 347921 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 20
Study 31012860 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app-based Mediterranean diet intervention (EXP)
Number of subjects: 100
Study 31012860 — intervention group
Group type: COMPARATOR
Intervention: Traditional standard-of-care counseling (SOC)
Number of subjects: 100
Study 31012860 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EXP and SOC
Number of subjects: 100
Study 27912927 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised rehabilitation programme (30-min sessions 3 days per week for 8 weeks in the hospital)
Number of subjects: 0
Study 27912927 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise programme
Number of subjects: 0
Study 27912927 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised rehabilitation programme
Number of subjects: 0
Study 25415290 — intervention group
Group type: EXPERIMENTAL
Intervention: Gardasil (HPV vaccine)
Number of subjects: 479
Study 25415290 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo vaccine
Number of subjects: 479
Study 22815050 — intervention group
Group type: EXPERIMENTAL
Intervention: EV-077 0.0125 mg/kg
Number of subjects: 7
Study 22815050 — intervention group
Group type: EXPERIMENTAL
Intervention: EV-077 0.125 mg/kg
Number of subjects: 7
Study 22815050 — intervention group
Group type: EXPERIMENTAL
Intervention: EV-077 0.375 mg/kg
Number of subjects: 7
Study 22815050 — intervention group
Group type: EXPERIMENTAL
Intervention: EV-077 0.75 mg/kg
Number of subjects: 7
Study 22815050 — intervention group
Group type: EXPERIMENTAL
Intervention: EV-077 1.25 mg/kg
Number of subjects: 7
Study 22815050 — intervention group
Group type: EXPERIMENTAL
Intervention: EV-077 1.875 mg/kg
Number of subjects: 7
Study 22815050 — intervention group
Group type: EXPERIMENTAL
Intervention: EV-077 2.5 mg/kg
Number of subjects: 7
Study 22815050 — intervention group
Group type: EXPERIMENTAL
Intervention: EV-077 (all doses)
Number of subjects: 7
Study 22815050 — intervention group
Group type: EXPERIMENTAL
Intervention: EV-077 (plasma concentrations above 20 ng/ml)
Number of subjects: 7
Study 22815050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 21079937 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine
Number of subjects: 20
Study 21079937 — intervention group
Group type: COMPARATOR
Intervention: Atosiban
Number of subjects: 20
Study 21079937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 19167698 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 84
Study 19167698 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 84
Study 17103040 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (800 mg TID)
Number of subjects: 49
Study 17103040 — intervention group
Group type: EXPERIMENTAL
Intervention: Satranidazole (300 mg TID with placebo at mealtime)
Number of subjects: 49
Study 15554765 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 29
Study 15554765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 11677707 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice-based anticoagulation management
Number of subjects: 452
Study 11677707 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based anticoagulation management
Number of subjects: 452
Study 11677707 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 452
Study 9141931 — intervention group
Group type: EXPERIMENTAL
Intervention: Midhumeral approach
Number of subjects: 60
Study 9141931 — intervention group
Group type: COMPARATOR
Intervention: Axillary approach
Number of subjects: 60
Study 8267110 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine with fluoxetine (N = 6)
Number of subjects: 34
Study 8267110 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine with valproic acid (N = 11)
Number of subjects: 34
Study 8267110 — intervention group
Group type: COMPARATOR
Intervention: Clozapine alone (N = 17)
Number of subjects: 34
Study 2961190 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB)
Number of subjects: 20
Study 2961190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29275118 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance (500 mg/m2 every 8 weeks for up to 2 years)
Number of subjects: 409
Study 29275118 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 409
Study 29275118 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance
Number of subjects: 409
Study 27120388 — intervention group
Group type: EXPERIMENTAL
Intervention: FOB Gold single-time testing
Number of subjects: 10000
Study 27120388 — intervention group
Group type: COMPARATOR
Intervention: OC-Sensor single-time testing
Number of subjects: 10000
Study 27120388 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tests
Number of subjects: 10000
Study 27120388 — intervention group
Group type: EXPERIMENTAL
Intervention: FOB Gold test at increased cutoff concentrations
Number of subjects: 10000
Study 26118519 — intervention group
Group type: EXPERIMENTAL
Intervention: TrP‐DN + EDU
Number of subjects: 12
Study 26118519 — intervention group
Group type: COMPARATOR
Intervention: TrP‐DN
Number of subjects: 12
Study 22886389 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure of the DAWBA to practitioners
Number of subjects: 235
Study 22886389 — intervention group
Group type: COMPARATOR
Intervention: Normal assessment (without DAWBA)
Number of subjects: 235
Study 20810979 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dairy calcium intake (median for tertiles: 156.5, 358.0, and 582.9 mg/d)
Number of subjects: 322
Study 20810979 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased serum 25(OH)D (14.5, 21.2, and 30.2 ng/mL for tertiles)
Number of subjects: 322
Study 20810979 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase of 1 SD in dairy calcium intake
Number of subjects: 322
Study 20810979 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase of 1 SD in serum 25(OH)D at the 6‐mo point
Number of subjects: 322
Study 18391295 — intervention group
Group type: EXPERIMENTAL
Intervention: da Vinci robotic virtual reality simulator (dV-Trainer)
Number of subjects: 0
Study 18391295 — intervention group
Group type: EXPERIMENTAL
Intervention: offline dV-Trainer
Number of subjects: 0
Study 18391295 — intervention group
Group type: COMPARATOR
Intervention: VR robotic surgery simulator
Number of subjects: 0
Study 16683415 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited resections
Number of subjects: 0
Study 16683415 — intervention group
Group type: EXPERIMENTAL
Intervention: Curative radiation therapy
Number of subjects: 0
Study 16683415 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated stereotactic body radiation therapy
Number of subjects: 0
Study 16683415 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant platinum-based chemotherapy
Number of subjects: 0
Study 16683415 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0
Study 16683415 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Number of subjects: 0
Study 14688709 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial resection for clinically unsuspected N2 nodal disease
Number of subjects: 0
Study 14688709 — intervention group
Group type: COMPARATOR
Intervention: No initial resection after neoadjuvant therapy for N2 nodal disease
Number of subjects: 0
Study 12097595 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV virus-like particle (VLP) vaccine administered intramuscularly at months 0, 2, 6, and a fourth dose at month 12 for half of the participants
Number of subjects: 0
Study 12097595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12097595 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV virus-like particle (VLP) vaccine
Number of subjects: 0
Study 9814730 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 800 microg once daily
Number of subjects: 36
Study 9814730 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 400 microg twice daily
Number of subjects: 36
Study 8029608 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone and hydrocortisone
Number of subjects: 116
Study 8029608 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone only
Number of subjects: 116
Study 8029608 — intervention group
Group type: COMPARATOR
Intervention: Dipyrone only
Number of subjects: 116
Study 8029608 — intervention group
Group type: COMPARATOR
Intervention: Hydration only
Number of subjects: 116
Study 8029608 — intervention group
Group type: COMPARATOR
Intervention: DW 50% only
Number of subjects: 116
Study 2741711 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior sleep
Number of subjects: 24
Study 2741711 — intervention group
Group type: COMPARATOR
Intervention: Awake control group
Number of subjects: 24
Study 31509228 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriasis lesions
Number of subjects: 10
Study 27637737 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdentures supported and retained by cantilevered bars on two canine implants (Group I)
Number of subjects: 20
Study 27637737 — intervention group
Group type: COMPARATOR
Intervention: Overdentures retained by straight bars on two canine implants and supported by two-first molar implants (Group II)
Number of subjects: 20
Study 27637737 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I
Number of subjects: 20
Study 27637737 — intervention group
Group type: COMPARATOR
Intervention: Group II
Number of subjects: 20
Study 27637737 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 25043606 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP genetic variants (rs1205, rs1800947, rs1130864, rs2808630, rs3093077)
Number of subjects: 727
Study 25043606 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP allele score as instrumental variable
Number of subjects: 727
Study 24284154 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative Radiation Therapy (RT)
Number of subjects: 1015
Study 24284154 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative Radiation Therapy (RT)
Number of subjects: 1015
Study 24284154 — intervention group
Group type: COMPARATOR
Intervention: No Radiation Therapy (RT)
Number of subjects: 1015
Study 22269199 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed bur for amalgam restorations (Group 1, n=9)
Number of subjects: 37
Study 22269199 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic tip for amalgam restorations (Group 2, n=10)
Number of subjects: 37
Study 22269199 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed bur for composite resin restorations (Group 3, n=8)
Number of subjects: 37
Study 22269199 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic tip for composite resin restorations (Group 4, n=10)
Number of subjects: 37
Study 22269199 — intervention group
Group type: COMPARATOR
Intervention: High-speed bur (for both materials)
Number of subjects: 37
Study 22269199 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic diamond tip (for both materials)
Number of subjects: 37
Study 19959686 — intervention group
Group type: EXPERIMENTAL
Intervention: OGG1 (S326C) polymorphism in current and former cigarette smokers
Number of subjects: 1604
Study 19959686 — intervention group
Group type: EXPERIMENTAL
Intervention: XRCC1 R194W polymorphism in regular cigarette smokers
Number of subjects: 1604
Study 16903842 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive heating (group 1)
Number of subjects: 19
Study 16903842 — intervention group
Group type: COMPARATOR
Intervention: Passive warming (group 2)
Number of subjects: 19
Study 15128017 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmat Futura system
Number of subjects: 21
Study 15128017 — intervention group
Group type: COMPARATOR
Intervention: Plasmat Secura system
Number of subjects: 21
Study 11358648 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol valerate (2 mg/day)
Number of subjects: 52
Study 11358648 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol valerate (2 mg/day) + Dienogest (2 mg/day)
Number of subjects: 52
Study 9000164 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45% saline oral ingestion (ORAL)
Number of subjects: 8
Study 9000164 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45% saline infusion (i.v.)
Number of subjects: 8
Study 9000164 — intervention group
Group type: COMPARATOR
Intervention: No fluid (NF)
Number of subjects: 8
Study 8173763 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 7
Study 8173763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 3630587 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 0
Study 3630587 — intervention group
Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 0
Study 31343548 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot Juice (BEET) 400-mg nitrate
Number of subjects: 27
Study 31343548 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline Malate (CitMal) 8 g
Number of subjects: 27
Study 31343548 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 27
Study 27853809 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciraparantag (100 to 300 mg IV)
Number of subjects: 80
Study 26033407 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately aerobic training (60-min sessions, 3-5 times a week for 6 months)
Number of subjects: 36
Study 26033407 — intervention group
Group type: COMPARATOR
Intervention: Sedentary lifestyle (no exercise training)
Number of subjects: 36
Study 23553596 — intervention group
Group type: EXPERIMENTAL
Intervention: deferasirox 5 mg/kg/day
Number of subjects: 166
Study 23553596 — intervention group
Group type: EXPERIMENTAL
Intervention: deferasirox 10 mg/kg/day
Number of subjects: 166
Study 23553596 — intervention group
Group type: EXPERIMENTAL
Intervention: deferasirox 20 mg/kg/day (dose-escalated from 10 mg/kg/day at Week 24)
Number of subjects: 166
Study 23553596 — intervention group
Group type: EXPERIMENTAL
Intervention: deferasirox >12.5-≤17.5 mg/kg/day
Number of subjects: 166
Study 23553596 — intervention group
Group type: EXPERIMENTAL
Intervention: deferasirox dosing strategies
Number of subjects: 166
Study 21464362 — intervention group
Group type: EXPERIMENTAL
Intervention: CALM (cognitive behavior therapy and pharmacotherapy recommendations)
Number of subjects: 1004
Study 21464362 — intervention group
Group type: COMPARATOR
Intervention: UC (usual care)
Number of subjects: 1004
Study 19100611 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adhesive resin cement (RelyX Unicem Aplicap, 3M ESPE, Germany)
Number of subjects: 49
Study 19100611 — intervention group
Group type: COMPARATOR
Intervention: Zinc phosphate cement (Richter & Hoffmann, Berlin, Germany)
Number of subjects: 49
Study 16688562 — intervention group
Group type: EXPERIMENTAL
Intervention: Process Oriented Memory Training (POT) group (n=24)
Number of subjects: 62
Study 16688562 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy Training (ST) group (n=22)
Number of subjects: 62
Study 16688562 — intervention group
Group type: COMPARATOR
Intervention: Low Dose Memory Training Control group (n=16)
Number of subjects: 62
Study 14687320 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 752
Study 14687320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 752
Study 11769634 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg once a day
Number of subjects: 233
Study 11769634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study 9263380 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus 3 mg/m2
Number of subjects: 16
Study 9263380 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus 5 mg/m2
Number of subjects: 16
Study 9263380 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus 10 mg/m2
Number of subjects: 16
Study 9263380 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus 15 mg/m2
Number of subjects: 16
Study 9263380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8513962 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin depot (n = 29)
Number of subjects: 57
Study 8513962 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cyclic oral contraceptive (n = 28)
Number of subjects: 57
Study 3799579 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone (Treatment A)
Number of subjects: 12
Study 3799579 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone with sucralfate (Treatment B)
Number of subjects: 12
Study 3799579 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone with sucralfate administered 2 h after (Treatment C)
Number of subjects: 12
Study 29303467 — intervention group
Group type: EXPERIMENTAL
Intervention: Kineflex|C cervical artificial disc (TDR)
Number of subjects: 269
Study 29303467 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 269
Study 26956654 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness strategies
Number of subjects: 7
Study 26956654 — intervention group
Group type: COMPARATOR
Intervention: Avoidance strategies
Number of subjects: 7
Study 25763936 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight reduction program for 3 months
Number of subjects: 22
Study 25763936 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 22
Study 24163147 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA) for dabigatran vs warfarin
Number of subjects: 35
Study 20883736 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7+MnCC vaccine
Number of subjects: 711
Study 20883736 — intervention group
Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 711
Study 20883736 — intervention group
Group type: COMPARATOR
Intervention: MnCC vaccine
Number of subjects: 711
Study 20883736 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccine groups
Number of subjects: 711
Study 17690599 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone extended-release 9 mg/day
Number of subjects: 36
Study 15118754 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intervention (CHWs with cleaning equipment and 5-9 visits over a year)
Number of subjects: 274
Study 15118754 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity intervention (CHWs with bedding encasements and fewer visits)
Number of subjects: 274
Study 11851734 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) injections
Number of subjects: 12
Study 11851734 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BTX‐A injections)
Number of subjects: 12
Study 9745864 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) 30 U/m2 per week
Number of subjects: 90
Study 9745864 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rhGH for the first year)
Number of subjects: 90
Study 9745864 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH)
Number of subjects: 90
Study 7803226 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic suggestions to increase cutaneous blood flow
Number of subjects: 10
Study 7803226 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic suggestions to decrease cutaneous blood flow
Number of subjects: 10
Study 7803226 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 3182477 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcholine (MCh) 5 x 10(-3) M injected after 1 hour of exercise in heat
Number of subjects: 15
Study 3182477 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcholine (MCh) 5 x 10(-3) M
Number of subjects: 15
Study 3182477 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcholine (MCh) 5 x 10(-4) M and above
Number of subjects: 15
Study 30420092 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive autonomy in surgical training
Number of subjects: 0